Have a look at our PowerPoint Introduction and Brochure describing deliverables, differentiators and case studies. Eight case studies can also be reviewed.


The objective of this project was to assist in identifying potential partnership candidates in order for the client to develop its cholesterol-reducing product for use as a nutraceutical in food and dietary supplements. Facilitating one or more suitable partnerships was a key objective.

The conclusion of a previous study was that the product would best be developed through a partnership with a suitably technically minded company with established sales and marketing in functional foods and/or dietary supplements. They should have the experience and resources to be able to pilot it through further process optimization, clinical trials, formulation trials, product registration and submission for regulatory approval.

In order for CPL to present the opportunity effectively to potential partners, a non-confidential introduction and a confidential Information Memorandum would be produced based on the work to date. Once partners were identified, CPL would advise on which business partner and business arrangement would be likely to suit the client’s strategic goals i.e. a best fit approach.


CPL developed a non-confidential introduction and a confidential Information Memorandum based on the work and IP position to date. The introduction described in broad terms the opportunity available to interested companies. It included outline information on the utility of the product, the desired outcome of the owners and the characteristics being sought in a partner.

Through its knowledge of the food ingredients and dietary supplements industries, CPL made suitable selected companies aware of the opportunity and determined whether this opportunity elicits their interest or not. In a number of cases, CPL contacted the appropriate person(s) in target companies directly to talk through the opportunity and its technical, clinical and commercial validity. This included participation at industry trade fairs in the USA and Europe.

For those companies with an interest, CPL obtained their agreement to a Confidential Disclosure Agreement, agreed in advance and then supplied the confidential Information Memorandum. As in the case of an acquisition, the IM contained proprietary information about the product, the clinical results and the market potential, including some outline indications of cost. The IM also outlined what sort of partnership was sought or would be acceptable and reviewed what characteristics would be most suitable in a partner. As required, CPL presented and talked through this IM with suitable candidates leading to direct meetings and discussions with the client on how to proceed.

Click to see the contents of the study or look below for an outline.

Table of Contents

Objective & Background


Principal Findings

  • Markets
    • Findings from previous study
    • Findings from this study
    • Market strategy
  • Competing Products
  • Assumptions Made about Med-205
    • Competition
    • Product
    • Process
    • Patent applications
  • Key success factors
  • Barriers to entry
  • Partners
  • Patent



Ongoing involvement by CPL Business Consultants

The present market for Cholesterol-lowering products

Potential Partner Profiles and Contact Reports

  • Summary of contacts
  • 71 Contact Reports
    • 27 Dietary Supplement
    • 7 Others

Non-Confidential Teaser

Confidential Information Memorandum



  • The idea
  • Introduction and background
    • The Company
    • The Project
  • Partnership
  • Investor considerations and business opportunity
  • Market description
  • IPR

Alfalfa and saponin background and rationale

  • Alfalfa as a botanical source of saponins
  • General alfalfa use
  • Conventional crude preparations
  • Saponin Glycosides

Pilot scale Production / Fractionation

  • Medicagenic Acid Saponin Extraction And Purification

Efficacy Testing in Animal trials

  • Diet
  • Animals
  • Experimental Designs
  • Initial Yield data and Efficacy Results

Food Applications


Further Information


  • Human Genotypes implicated in mechanisms for dietary Plasma Cholesterol Reduction


  • Context of Alfalfa Extract under TITLE 21–FOOD AND DRUGS
  • US New Dietary Ingredient status “NDI”
  • The SIDI (Standardized Information on Dietary Ingredients ) Protocol
  • 27 News Items

5 Tables

5 Figures

Share this project: